Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Sen, Zhang, Zhe, Wang, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498593/
https://www.ncbi.nlm.nih.gov/pubmed/31046803
http://dx.doi.org/10.1186/s13045-019-0736-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498593/
https://www.ncbi.nlm.nih.gov/pubmed/31046803
http://dx.doi.org/10.1186/s13045-019-0736-3

Ejemplares similares